Literature DB >> 20545594

QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique.

Scott D Grosse1, Lisa A Prosser, Keiko Asakawa, David Feeny.   

Abstract

The use of utility weights for the calculation of quality-adjusted life years is particularly problematic for pediatric health states. This article reviews variability in utility weights for intellectual disability and permanent hearing loss in economic evaluations of newborn screening and childhood immunizations. Utility weights for severe intellectual disability ranged from 0.06 to 0.74. Most studies either did not vary these utility weights in sensitivity analyses or assumed low variability; consequently, the robustness of cost-effectiveness estimates was not fully assessed. Two recently published catalogs of utility weights for pediatric health states also show wide divergences in estimates. More work is needed to establish measures of health utilities for childhood health states in order to allow for comparable assessments of pediatric interventions.

Entities:  

Mesh:

Year:  2010        PMID: 20545594     DOI: 10.1586/erp.10.24

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  13 in total

Review 1.  Autism spectrum disorders: a review of measures for clinical, health services and cost-effectiveness applications.

Authors:  Nalin Payakachat; J Mick Tilford; Erica Kovacs; Karen Kuhlthau
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2012-08       Impact factor: 2.217

2.  Predicting health utilities for children with autism spectrum disorders.

Authors:  Nalin Payakachat; J Mick Tilford; Karen A Kuhlthau; N Job van Exel; Erica Kovacs; Jayne Bellando; Jeffrey M Pyne; Werner B F Brouwer
Journal:  Autism Res       Date:  2014-09-25       Impact factor: 5.216

Review 3.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

4.  Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State.

Authors:  Yao Ding; John D Thompson; Lisa Kobrynski; Jelili Ojodu; Guisou Zarbalian; Scott D Grosse
Journal:  J Pediatr       Date:  2016-02-11       Impact factor: 4.406

5.  Preference-based health-related quality-of-life outcomes in children with autism spectrum disorders: a comparison of generic instruments.

Authors:  J Mick Tilford; Nalin Payakachat; Erica Kovacs; Jeffrey M Pyne; Werner Brouwer; Todd G Nick; Jayne Bellando; Karen A Kuhlthau
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

Review 6.  Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2020-11-02

7.  Decision analysis, economic evaluation, and newborn screening: challenges and opportunities.

Authors:  Lisa A Prosser; Scott D Grosse; Alex R Kemper; Beth A Tarini; James M Perrin
Journal:  Genet Med       Date:  2012-04-05       Impact factor: 8.822

8.  Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening.

Authors:  Astrid Langer; Rolf Holle; Jürgen John
Journal:  BMC Health Serv Res       Date:  2012-09-04       Impact factor: 2.655

9.  Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis.

Authors:  Scott D Grosse
Journal:  Healthcare (Basel)       Date:  2015-11-11

10.  Cost and Cost-Effectiveness Assessments of Newborn Screening for Critical Congenital Heart Disease Using Pulse Oximetry: A Review.

Authors:  Scott D Grosse; Cora Peterson; Rahi Abouk; Jill Glidewell; Matthew E Oster
Journal:  Int J Neonatal Screen       Date:  2017-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.